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Meningoencephalomyelitis of unknown etiology (MUE) is an umbrella term used to 
describe a group of noninfectious inflammatory central nervous system (CNS) diseases in dogs. 
There are many subtypes of MUE identified in the canine population, including granulomatous 
meningoencephalomyelitis, necrotizing meningoencephalitis, necrotizing leukoencephalitis, 
steroid responsive meningitis arteritis, eosinophilic meningoencephalomyelitis, and greyhounds 
non-suppurative meningoencephalitis. The etiology of MUE remains unknown, but it is 
suspected to have an autoimmune pathogenesis. Emerging research points to genetic and 
environmental factors that are likely to play a role as well. Because histopathology from brain 
biopsy or necropsy is required for definitive diagnosis, antemortem diagnostic guidelines have 
been published in the literature. Treatment with glucocorticoids remain the standard of care for 
these patients. The prognosis is fair to guarded, with improved survival times when more than 
one immunomodulatory drug (IMD) is utilized. One IMD, cytosine arabinoside (CA), has been 
applied to dogs with MUE due to its ability to cross the blood brain barrier, low incidence of 
adverse effects, and prolonged survival times reported.  
In spite of its increasing application for dogs with MUE, there is no standard 
administration protocol for CA. Various protocols have been proposed, all requiring either 24-48 
hours (h) of hospitalization or one prolonged day of hospitalization lasting longer than 12h. 
Thus, a study was designed to investigate the pharmacokinetic (PK) properties of CA when 
administered as repeated subcutaneous injections over an 8h period to dogs with MUE in order 
to determine if this amenable administration protocol is a viable alternative to more laborious 
CRI administration. The primary objective was to describe PK parameters of CA when 






to determine if CA concentrations reach its therapeutic target (> 1 µg/mL) with both routes of 
administration. The final objective was to report the short term outcome of each patient 3 months 
following initiation of treatment. We hypothesized that both routes of administration would 
result in CA concentrations that exceeded its therapeutic target concentration at 1h and 8h 
following initiation of treatment, indicative of the proposed SC protocol providing sustained 
plasma CA concentrations throughout administration. Additionally, we hypothesize that most 
dogs receiving this protocol would have a favorable outcome, with the majority being alive 3 
months after initiating treatment receiving only 1 oral IMD (either prednisone or prednisolone). 
Dogs with MRI and CSF findings compatible with an antemortem diagnosis of MUE 
weighing greater than 2.5 kilograms were recruited for this study, and 8 dogs met the inclusion 
criteria. Dogs received CA as a CRI (200 mg/m2 IV over 24h) initially, followed by a SC 
protocol (50 mg/m2 every 2h for 4 treatments) four weeks later. Plasma CA concentrations were 
measured by high-pressure liquid chromatography-tandem mass spectrometry (HPLC-MS). For 
both the IV and SC protocols, PK parameters were calculated including maximum plasma 
concentration (Cmax), observed area under the curve (AUC0-24) using the trapezoidal method, 
plasma concentrations at 1h and 8h after initiating treatment (C1 and C8, respectively), and 
duration of time plasma concentration exceeded 1 µg/mL (T>1). Time to Cmax (Tmax) was 
calculated for the SC protocol only. Wilcoxon sign rank tests were performed to compare Cmax, 
C1, C8, and T>1 between the CRI and SC protocols. McNemar's tests were used to compare the 
number of dogs that achieved plasma concentrations greater than 1 µg/mL at 1h and 8h 
following CA administration between the two administration protocols.  
Median peak CA concentration for the SC protocol (3.40 µg/mL, range 1.60-9.70 µg/mL) 






following SC administration were significantly higher than when administered as a CRI, with a 
median of 3.4 µg/mL (range: 1.6-9.7 µg/mL) and 1.09 (range: 0.77-1.69 µg/mL; P = 0.0156), 
respectively. Median concentration at 1h and 8h following initiation of treatment was 
significantly higher for the SC protocol (CA1 2.28 µg/mL, range 0.97-2.67; CA8 1.83 µg/mL, 
range 0.77-2.84) compared to the CRI (CA1 0.01 µg/mL, range 0-0.45; CA8 0.74 µg/mL, range 
0.67-1.11; P = 0.01). T>1 was also significantly higher for the SC protocol (9.25h, range: 4.5-
10.5) than for the CRI protocol (3.13h, range: 0-9.75; P = 0.039). Five of the 8 dogs remained 
alive at the time of follow-up 3 months later, and only 1 of these 5 dogs was receiving more than 
one oral IMD at that time (aside from prednisone or prednisolone). 
This study demonstrated that CA when administered as repeated SC injections over an 8h 
period achieved consistent and prolonged exposure in the plasma of dogs with MUE. Cytosine 
arabinoside (CA) exceeded its target concentration of 1 µg/mL at 1h and 8h following initiation 
of treatment via the proposed SC protocol, rarely meeting this target with the CRI protocol 
administered. These findings indicate further research investigating the therapeutic target of CA 
in dogs with MUE. Additionally, further research is warranted to determine if there is a 
significant difference in prognosis for dogs receiving the proposed SC protocol at the time of 
diagnosis when compared to more laborious CRI administration.  
Based on currently available data, the authors recommend the following protocol for CA 
in dogs with MUE: CA 100-200 mg/m2 intravenously as a CRI over 24h at the time of diagnosis, 
followed by 50 mg/m2 every 2 hours for 4 doses every 4 weeks. This SC protocol can be 
administered on an outpatient basis, reducing prolonged hospitalization or repeated hospital 
visits for treatment, reducing cost to the client, and most importantly, reducing pain to the patient 
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CHAPTER 1: LITERATURE REVIEW MENINGOENCEPHALOMYELITIS OF 
UNKNOWN ETIOLOGY  
1.1 PROPOSED ETIOLOGY 
Meningoencepahlomyelitis of unknown etiology (MUE) is an umbrella term used to 
describe a group of noninfectious inflammatory central nervous system (CNS) diseases in dogs, 
including predominantly granulomatous meningoencephalomyelitis (GME), necrotizing 
meningoencephalitis (NME), and necrotizing leukoencephalitis (NLE) (Vitale 2018). All three of 
these disease entities require histopathology for definitive diagnosis, however, there are 
recommendations present in the literature for assignment of an antemortem diagnosis of MUE. 
Other noninfectious inflammatory CNS disease exist, such as steroid responsive meningitis 
arteritis (SRMA), eosinophilic meningoencephalomyelitis (EME), and greyhounds non-
suppurative meningoencephalitis (Vitale 2018). The noninfectious inflammatory CNS diseases in 
dogs are collectively termed MUE when a histopathological diagnosis is lacking and are 
suspected to be immune mediated in origin.  
An autoimmune pathogenesis has been suspected based upon the histopathological 
features of the CNS in dogs with MUE. This primary theory has been derived from several 
studies which were performed to elucidate the cell types present within these inflammatory 
lesions in dogs (Kipar 1998, Park 2012). More specifically, a delayed type hypersensitivity 
reaction has been suggested by Kippar et al. due to the presence of macrophages and T 
lymphocytes within inflammatory lesions of dogs with GME (Kipar 1998). Park et al. 
demonstrated similar findings present in a broader population of dogs with inflammatory CNS 
disease, including diagnoses of NME, NLE, and GME (Park 2012). In this population of dogs, 






positive cells (T-cells), and CD163 positive cells (macrophages). The distribution of these cells 
differed anatomically between NME, NLE, and GME. In those dogs diagnosed with NME, 
malacic changes were predominantly localized to the cerebral cortex. Dogs diagnosed with NLE 
predominantly had malacic changes present in the cerebral white matter and thalamus. Lastly, 
dogs with GME seemed to have the widest distribution, with lesions being found in the cerebral 
white matter, cerebellum, and brainstem. There was no significant difference in the proportion of 
B-cells and macrophages between the groups, but dogs with GME had a higher proportion of T-
cells when compared to dogs with NLE and NME. In turn, Park et al. concluded that the 
predominant cell types found in dogs with NME, NLE, and GME were lymphocytes and 
macrophages, with T-cells being the predominating cell type in GME. 
Genetic risk factors have also been identified to support MUE’s immune-mediated 
pathogenesis. Two genetic risk loci have been identified in Pug dogs with NME, particularly a 
region within dog leukocyte antigen (DLA) class II complex on chromosome 12 (Barber 2011). 
Dog leukocyte antigen class II haplotypes have been associated with development of non-
suppurative meningoencephalitis in population of greyhounds in Ireland as well (Shiel 2014). 
Similarly, genetic risk loci have been identified in Maltese and Chihuahua dogs (Schrauwen 
2014). In Maltese dogs, regions of significance were found on chromosomes 4 and 15. These 
chromosomes contain information pertinent for genes which control regulation of immune 
system function based on haplotype analysis and fine-mapping performed, namely the ILR7 and 
FBXW7 genes. Additionally, a shared genetic risk between Pug, Maltese, and Chihuahua dogs 
was discovered, associated with chromosome 15 and DLA class II complex. These investigations 
have begun to elucidate the genetic risk factors that play a role in development of MUE in toy 






In addition to genetic risk factors, various infectious etiologies have been excluded as the 
inciting cause of MUE. A metagenomic investigation was performed in 22 dogs, utilizing 11 
dogs with MUE and 11 dogs with noninflammatory central nervous system disease inconsistent 
with MUE as negative controls (Hoon-Hanks 2018). Cerebrospinal fluid or brain tissue samples 
were collected, and their RNA and DNA extracted for shotgun metagenomic sequencing, which 
revealed no candidate etiologic agents for dogs with MUE. Due to the fact that viruses 
(particularly arbovirus and bornavirus) have precipitated non-suppurative encephalitides in other 
species, they have also been investigated as etiologic agents (Barber 2012, Collinet 2020). Dogs 
diagnosed with GME and NME were evaluated by broadly reactive polymerase chain reaction 
for adenoviruses, bunya viruses, coronaviruses, enteroviruses, flaviviruses, herpesviruses, 
paramyxoviruses, and parechoviruses, in addition to thorough testing for mycoplasmas by means 
of polymerase chain reaction (PCR), culture, and immunohistochemistry (IHC) (Barber 2012). 
No viral nucleic acids were found. Cerebrospinal fluid of dogs with MUE have also been tested 
via reverse-transcriptase PCR for the presence of astrovirus and bornavirus specifically, and 
neither were identified. Five of said cases were positive for Mycoplasma genus (1/5 GME and 
4/25 NME) via PCR and Mycoplasma canis was cultured from 8 cases (4/5 GME and 4/8 NME) 
but ultimately M. canis was not identified on IHC staining of any of these cases. The overall 
negative results of broad viral testing makes a viral etiologic agent unlikely in dogs, but the 
possibility of a viral etiology that has yet to be discovered cannot be entirely eliminated (Barber 
2012, Collinet 2020). Additionally, given that MUE encompasses a heterogenous collection of 
diseases, it is possible that the inciting factor of each is slightly varied. 
Other factors have begun to be investigated in dogs with MUE as well. One study 






home address), signalment, body weight, body condition score, and vaccination status (Barnes 
Heller 2019). None of the factors investigated were associated with an increased risk of 
diagnosis. A different investigation, however, found that Prevotellaceae is significantly less 
abundant in the gut of dogs with MUE when evaluating their fecal microbiome, possibly 
suggestive of difference in the gut microbiota contributing to the development of MUE (Jeffrey 
2017). It is overall apparent that genetic risk factors likely play a role in development of MUE, 
while the effects of other environmental factors require more investigation in a larger population 
of affected dogs. 
 
1.2 PREVALENCE AND INCIDENCE  
Prevalence data is imperative to better understand the impact that MUE has on the canine 
population as a whole; however, there are no data available pertaining to its prevalence in the 
general canine population. While a 2010 metanalysis on MUE identified 457 cases reported in 
the literature between 1962-2008, the canine population within each individual institution was 
not reported (Granger 2010). Therefore, prevalence could not be determined within the canine 
population as a whole. The only population in which the prevalence of MUE has been 
investigated is in the French Bulldog (Mayousse 2017). A retrospective review of all French 
Bulldogs evaluated for neurological disease between 2001-2016 discovered that 25% of all 
encephalopathies were attributed to MUE. The only encephalopathic etiology more prevalent in 
this population was neoplasia, accounting for 36.8% of encephalopathies in neurological French 
Bulldogs. Further investigation is warranted to determine the prevalence of MUE in the general 







In the absence of additional information pertaining to its prevalence, valuable information 
can still be extracted from those studies that have been able to investigate the incidence of MUE 
in dogs presenting for neurological disease. In the few studies available, the incidence of 
inflammatory brain disease diagnosed in neurological dogs has ranged from 12.6-14% 
(Fluehmann 2006 and Tipold 1995). Upon retrospective review of dogs presenting to a referral 
hospital in Switzerland between 1989-2000, 14% of dogs presenting with neurological signs of 
either the brain, spinal cord, or peripheral nervous system were diagnosed with 
inflammatory/infectious disease (Fluehmann 2006). Unfortunately, MUE (nor any of its 
associated histopathological diagnoses) was not included in the list of assigned diagnoses. 
Rather, the diagnoses included within the inflammatory/infectious category included a space-
occupying lesion, canine distemper, otitis media-interna, and SRMA. Given that diagnoses of 
neoplasia and metastatic meningitis were amongst the other disease categories listed, it is 
suspected that dogs with MUE would have fallen into the category of space-occupying 
inflammatory/infectious disease. This category could theoretically also include intracranial 
abscess or granuloma, therefore, more precise data pertaining to MUE cannot be fully 
extrapolated from this study.  
One previous study provided more specific clinical diagnoses of inflammatory disease in 
dogs, including a multitude of infectious and noninfectious etiology of inflammatory diseases 
(Tipold 1995). Tipold found that MUE accounted for 12.6% of all histopathologically diagnosed 
inflammatory CNS disease in dogs between 1988-1993. While this percentage may not appear 
remarkably high, the only noninfectious disease process which surpassed MUE in this population 
of 220 dogs was steroid responsive meningitis arteritis (SRMA) (incidence of 14.5%), which has 






more research is warranted to better define both the incidence and prevalence of MUE, but the 
data available suggest that it is a fairly common cause of CNS disease in dogs.  
 
1.3 ANTEMORTEM DIAGNOSIS 
An antemortem diagnosis of MUE requires systemic testing, including infectious disease 
testing, followed by magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analysis. 
Recommended systemic testing includes screening for both metabolic and neoplastic disease via 
complete blood counts, chemistry panel, urinalysis, total thyroid level, baseline cortisol, and 
thoracic and abdominal imaging (Granger 2010, Vitale 2018). Pertinent infectious testing is also 
recommended, and ultimately depends on the geographical region and patient history. Pertinent 
infectious agents that can affect the CNS in dogs include protozoa (Toxoplasma gondii and 
Neospora caninum), viruses (rabies and canine distemper virus), tick-borne diseases (Ehrlichia 
canis and Anaplasma phagocytophilum), and fungi (Blastomyces dermatitidis, Cryptococcus 
neoformans, and Coccidiodes immitis).  
Should an inciting cause of neurological signs not be found, advanced imaging is 
recommended to evaluate the neuroanatomical region of interest. Brain and spinal cord MRI are 
the gold standard imaging modality. Cerebrospinal fluid (CSF) analysis is subsequently 
performed to better characterize the type of inflammatory population present. The three largest 
subtypes of MUE (being GME, NME, and NLE) have neurolocalization predilections that can be 
appreciated on MRI. Granulomatous meningoencephalomyelitis affects the cerebrum, 
cerebellum, brainstem, or spinal cord, and can be present as a focal, disseminated, or ocular form 
of the disease (Vitale 2018). On histopathologic examination, these lesions consist of a mixed 






distributed in the CNS, with NME having a predilection for the cerebrum and NLE having a 
predilection for the cerebrum and brainstem (Vitale 2018). The histopathologic characteristics 
associated with NME and NLE include inflammation and necrosis affecting the junction of the 
gray and white matter or solely the white, respectively (Vitale 2018). These histopathologic 
findings are required to make a definitive diagnosis postmortem, but are often lacking when 
assigning an antemortem diagnosis due possible adverse outcomes from brain biopsy, including 
seizure, stupor, paresis, ataxia, loss of consciousness, or other post-procedure complication such 
as aspiration pneumonia (Flegel 2012, Granger 2010). With brain biopsy having a morbidity rate 
of 27-29% (Flegel 2012, Shinn 2020), it is understandable why many owners elect to forgo this 
procedure and rely upon antemortem diagnostic criteria. 
A large metanalysis performed by Granger and colleagues recommends three major 
antemortem diagnostic criteria: 1) single or diffuse intra-axial hyperintense lesion(s) on T2-
weighted MRI; 2) CSF hypercellularity with >50% mononuclear cells (lymphocyte and/or 
monocytes); 3) negative infectious disease testing. These major criteria were corroborated by a 
more recent review of noninfectious inflammatory diseases in dogs; however, this review applied 
a broader description of the disease process than did Granger et al. Vitale and Foss described 
CSF findings reported in dogs with MUE in addition to other inflammatory CNS disorders 
(Vitale 2018). These findings included predominantly a mononuclear pleocytosis, in addition to 
albuminocytologic dissociation, neutrophilic pleocytosis (specifically SRMA), and eosinophilic 
pleocytosis (specifically EME) (Vitale 2018). Granger and colleagues also suggested excluding 
several noninfectious inflammatory CNS diseases in dogs from the category of MUE, which 
were encompassed in Vitale and Foss’s review, such as SRMA, EME, spinal cord only MUE, 






would seem prudent to include all forms of noninfectious inflammatory CNS disease that are 
suspected to have an autoimmune pathogenesis under the category of MUE. Subsequently, other 
factors such as signalment, lesion localization on neurological examination and MRI, and CSF 
cell type predominance can be used clinically to help prioritize which subtype(s) may be most 
likely.  
 
1.4 TREATMENT AND PROGNOSIS 
There is no standardized treatment for MUE and the prognosis is variable. 
Glucocorticoids are the mainstay therapy, and at one time were the sole therapy used for MUE. 
Prednisone and prednisolone at dosages of 1-2 mg/kg/day orally when used as a monotherapy 
has been associated with median survival times (MST) of 28-602 days (Flegel 2011, Jung 2007, 
Mercier 2015, Pakzody 2009). Improved outcomes have been documented when additional 
immunomodulatory agents are used, such as azathioprine (MST 1824 days for MUE; Wong 
2010), cytosine arabinoside (MST 26 to >1095 days; Lowrie 2013, Lowrie 2016, Smith 2009, 
Stee 2020, de Stefani 2007, Menaut 2008, Zarfoss 2006), cyclosporine (MST 240-930 days for 
GME and NME; Adamo 2007, Gnirs 2006, Jung 2007, Pakozdy 2008), lomustine (MST 329 
days for GME and 329 days for NME; Flegel 2011), and mycophenolate (MST 250-731 days for 
MUE; Baroon 2016, Woolcock 2015). The studies investigating treatment of MUE all have a 
fairly small sample size with an average of 10 dogs (range: 7-16) for those pertaining to 
glucocorticoids alone and 22 dogs (range: 3-83) for those pertaining to use of multiple 
immunomodulatory drugs. Taking these data into account, it is evident that treatment with more 







Studies have found surviving the initial phase of diagnosis is likely a positive prognostic 
indicator. More specifically, 1/3 of dogs diagnosed with MUE are known to succumb to their 
disease within 72 hours of diagnosis (Lowrie 2018). Another study found that 1/4 of dogs 
diagnosed with MUE die or are euthanized within 7 days of diagnosis (Cornelis 2016). Indicators 
associated with a positive prognosis include younger age at diagnosis (Oliphant 2017), 
presenting with focal forebrain signs (Muanana 1998), presenting within 7 days of the onset of 
clinical signs (Baroon 2016), resolution of MRI abnormalities 3 months after initiating treatment 
(Lowrie 2013), and surviving 3 months (Lowrie 2013, Smith 2009) and 6 months following 
initiation of treatment (Stee 2020). Conversely, presenting with seizures or an altered mentation 
(Cornelis 2016), discontinuing treatment prior to resolution of lesions appreciated on MRI 
(Lowrie 2013), and the appearance of midline shift on MRI (Oliphant 2017) have all been 
identified as negative prognostic indicators. With 15% of cases dying or being euthanized prior 
to receiving treatment, it is clear that this is a severe disease process in dogs warranting further 







CHAPTER 2: LITERATURE REVIEW OF CYTOSINE ARABINOSIDE 
 
2.1 MECHANISM OF ACTION 
Cytosine arabinoside (CA) is a synthetic nucleoside analogue of cytidine with 
antineoplastic and anti-inflammatory properties. It is S-phase specific and causes competitive 
inhibition of DNA polymerase in mitotically active cells, thus preventing DNA replication and 
halting the cell cycle (Mulder 1975, Scott-Moncrief 1991, Gmeiner 2003, Withrow 2012, Zarfoss 
2006). It also inhibits DNA repair and membrane protein glycosynthesis by altering 
topoisomerase function (Griffin 1982, Withrow 2012).  It is a water-soluble compound that is 
rapidly transported intracellularly by means of facilitated diffusion via nucleoside transporters 
within the cell membrane, similar to organic nucleosides uptake (Groothius 2000, Mulder 1975). 
Once transported intracellularly, CA undergoes repeated phosphorylation via various kinases as 
it is metabolized to its biologically active form, CA-triphosphate (DeAngelis 1992, Groothius 
2000, Mulder 1975, Wiley 1984). Throughout this process cytidine deaminase and 
deoxycytidylate deaminase metabolize CA into its biologically inactive forms for excretion 
(Mulder 1975, DeAngelis 1992, Wiley 1984). There is known species variation in deaminase 
activity that is thought to contribute to the degree of its penetration into the central nervous 
system. Subsequently, variations in indicated dosage and agent efficacy would be expected 
across species (Groothius 2000). With that being said, patients with inflammatory CNS disease 
have alteration in the function of their blood-brain barrier due to changes in architecture of  
endothelial tight junctions, disruption of the basement membrane, and increased vascular 
permeability due to upregulation of cytokines, metalloproteinases, and nitrous oxide, 






conditions could therefore affect CA penetration into CSF and subsequently the brain and spinal 
cord parenchyma. Due to its ability to halt the cell cycle, CA has both antineoplastic and anti-
inflammatory properties.  
 
2.2 METABOLISM AND EXCRETION 
Data regarding CA metabolism and excretion is available in human literature and 
minimally in veterinary literature (rodents and dogs). In humans and rats, CA undergoes 
facilitated diffusion to gain intracellular access via nucleoside transporters within the cell 
membrane (Mulder 1975, Groothuis 2000). It is then phosphorylated to CA-monophosphate via 
deoxycytidine kinase, undergoes further phosphorylation to CA-diphosphate via monophosphate 
kinase, and then CA-triphosphate via nucleoside diphosphate kinase, which is the biologically 
active and predominant intracellular form (Mulder 1975, DeAngelis 1992). The active form is 
then incorporated into DNA, causing inhibition of DNA polymerase. It is metabolized primarily 
in the liver via deamination by deoxycytosine deaminase to its biologically inactive form, uracil 
arabinoside (UA) (Mulder 1975, DeAngelis 1992). UA undergoes renal excretion over the 
following 24 hours, which occurs more rapidly from the plasma than from CSF (DeAngelis 
1992). The mean plasma and CSF elimination half-life reported in healthy dogs is 64 and 165 
minutes, respectively (Scott-Moncrieff 1991). These data available regarding elimination of CA 
in dogs is in agreement with previously published data in humans, indicating that CA is 
eliminated more rapidly from the plasma than CSF (Mulder 1975). Whether CA is time or 








2.3 INVESTIGATION OF CYTOTOXIC EFFECTS  
There are no studies available in the literature evaluating pharmacodynamic end points of 
CA in dogs with inflammatory brain disease. An in vitro assessment of CA’s cytotoxicity has 
been performed utilizing healthy mouse and human bone marrow colony forming cells in 
addition to human leukemic colony forming cells obtained from the marrow and peripheral blood 
cells of patients with chronic myeloid leukemia (Greenberg 1976). This study demonstrated both 
time- and concentration dependency of CA in rodent cell lines, and concentration-dependency in 
leukemic human cell lines. When mouse bone marrow granulocyte progenitor cells (GPC) were 
exposed to CA for a shorter duration of time (1 and 4 hours), cytotoxicity increased with 
increasing dosages. Ultimately GPC survival plateaued once CA concentrations were 10 µg/mL. 
These data suggested that CA activity is concentration dependent in the mouse. These cells were 
then exposed to 10 µg/mL of CA for a longer duration of time (8 hours), and a statistically 
significant increase in GPC cytotoxicity was found. The mouse GPC were also exposed to a 
relatively low concentration of CA (0.01-0.1 µg/mL) over an extended duration of time (10-day 
period) and markedly decreased cell survival was noted beyond what was seen with other 
exposure periods. This demonstrates some time-dependent properties of the drug in this species 
as well. When evaluating healthy human marrow, a dose-related decreases in GPC was found 
when incubated with 0.01, 0.1, 1.0 and 10 µg/mL CA for both 1 and 4-hour periods. There was 
no significant difference between the duration of CA exposure and GPC death. When evaluating 
human leukemic colony forming cells similar dose-related cytotoxic effects were seen, but 
increased cytotoxicity was found in the leukemic cell population compared to the healthy cells 
when a shorter exposure period (1-hour) to a higher concentration of CA (10 µg/mL) was 






of exposure were utilized, whereas lower dosages were needed to achieve the same cytocidal 
activity when longer drug exposure was implemented. The authors thus recommended 
administration of CA via a continuous rate infusion at a low-dose or as intermittent high dose 
therapy.  
Interestingly, a different study found that CA was predominantly time-dependent rather 
than concentration dependent in healthy human marrow (Raijmakers 1985). When normal human 
bone marrow cells were incubated with increasing concentrations of CA (up to 10-5 M) for one 
hour, granulocyte-macrophage colony forming unit (CFU-GM) growth was not even decreased 
by 50% when compared to control cultures. As the time of incubation was increased to 24 hours, 
there was a significant reduction in the number of CFU-GM when compared to control cultures. 
Furthermore, the inhibitory concentration of CA reducing the number of colonies to 50% of the 
control culture (IC50) became greater than 2 logs lower after 5 days of incubation when 
compared to 24 hours of incubation. The rate of CA deamination at different cell concentrations 
was also evaluated. After a 5-day incubation of 106 cells/mL and 105 cells/mL, 0% and 90% of 
CA remained detectable in the supernatant, respectively. The reduced deamination of CA with 5-
day incubation of 106 cells/mL was suspected to be related to an increased rate of deamination at 
this concentration, resulting decrease in efficacy (reduced exposure). Based on these data, CA 
was found to have time dependent cytotoxicity in human bone marrow cells.  
Very few reports have been published evaluating the efficacy of CA at a cellular level in 
dogs. In 2014, Pawlak et al. evaluated the effect of common anticancer agents on induction of 
apoptosis in canine lymphoma and leukemia cell lines, including CA (Pawlak 2014). In the 
tested B-cell lymphoma (CLBL-1) and B-cell (GL-1) and T-cell leukemia (Jurkat) cell lines, CA 






72 hours of incubation with CA (1 µg/mL). This was most notable in CLBL-1. This research 
group performed another in vitro study, which more specifically evaluated the sensitivity of 
canine lymphoma cells to CA (Pawlak 2016). They found that CA had moderate efficacy 
(decrease in viable lymphocytes) when incubating canine lymphoma cells in vitro with 1 µg/mL 
of CA over 72 hours. It is important to bear in mind that neoplastic cells can exhibit altered 
chemosensitivity and pharmacodynamic properties (Pawlak 2016). Thus, these results may not 
accurately predict CA activity against the non-neoplastic inflammatory cells that mediate MUE, 
which has yet to be investigated.  
Based on the data available, it appears that CA exhibits both time- and concentration-
dependent cytotoxic properties with significant species variation. Further in vitro and in vivo 
studies are indicated to better evaluation pharmacodynamic end points in dogs with 
inflammatory brain disease. 
 
2.4 APPLICATION TO CANINE PATIENTS 
CA is a frequently used antineoplastic agent indicated in human patients for treatment of 
lymphoma and acute myeloid leukemia. It has been utilized in canine patients as treatment for 
various forms of lymphoma (including those with bone marrow or CNS involvement or cases of 
relapse), leukemia, and optic neuritis of non-infectious origin (Alvarez 2006, Bedos 2020, 
Gillem 2015, LaRue MK 2018, Marconato 2008, Pawlak 2014, Pawlak 2016). It has become an 
emerging treatment option for meningoencephalomyelitis of unknown etiology (MUE) in dogs 
due to favorable survival data. The earliest report of CA being used for treatment of MUE was 
published in 2002. Nuhsbaum et al. described CA being administered subcutaneously (50 






granulomatous meningoencephalitis (Nuhsbaum 2002). The dog was sent home with prednisone 
(2 mg/kg every 24 hours tapered over 4 weeks) and continued to receive CA in this fashion every 
3 weeks. The dog was still alive 12 months after her diagnosis.  
CA was also associated with a favorable prognosis in a prospective study utilizing it as 
treatment in combination with prednisone in 10 dogs (Zarfoss 2006). In this prospective study, 
partial to complete remission was found in all dogs upon initiation of prednisone (1-2 mg/kg 
every 12 hours tapered over 3 months) and CA (50-100 mg/m2 subcutaneously every 12 hours 
for 48 hours). CA was administered in this fashion every 3 weeks for 4 months, subsequently 
increasing the interval between treatments by 1 week every 4 months. The median survival time 
reported was 531 days (range 46-1025 days) (Zarfoss 2006). These findings are suggestive of 
prolonged survival times being associated with this combination of drugs. 
Prolonged survival was also reported when retrospectively evaluating a population of 
dogs that were treated with a similar protocol after being diagnosed with MUE (Menaut 2008). 
All 11 dogs received prednisolone (1-2mg/kg every 12 hours tapered over 3 months) and CA (50 
mg/m2 subcutaneously every 12 hours for 48 hours). CA was initially administered every 4 
weeks, increasing the interval between treatments by 1 week every 4 weeks if possible (Menaut 
2008). In this population of dogs, 58% were still alive 2 years after their initial diagnosis, with 
survival times ranging from 78-603 days (Menaut 2008). Subsequently, another study aimed to 
retrospectively evaluate an intravenous protocol. In this 2009 study, 7 dogs received 
prednisolone (40 mg/m2 every 24 hours tapered over 8 weeks) and CA (100 mg/m2 intravenously 
over 24 hours) (Smith 2009). This protocol was also associated with a positive outcome for many 






months following diagnosis. In Zarfoss’s, Menaut’s, and Smith’s study populations, no signs of 
myelosuppression nor other adverse effects were noted when administering CA to dogs. 
Due to its lack of adverse effects and reported favorable outcomes, CA continued to be 
used in dogs for treatment of MUE. In 2016, Lowrie and colleagues performed the first 
investigation of the effect of a CRI of CA on mortality in dogs with MUE (Lowrie 2016). It was 
discovered that CA administered as a CRI (100 mg/m2 over 24 hours once) following initial 
diagnosis of MUE provided a survival advantage over initial treatment of CA as repeated SC 
injections (50 mg/m2 every 12 hours over 48 hours). Survival data was obtained 3 months 
following diagnosis, and 90% of dogs receiving the CRI protocol remained alive at 3 months 
while only 44% of dogs receiving the SC protocol had survived. A more recent study was able to 
provide a significantly longer follow-up period following administration of CA upon initial 
diagnosis. When CA was administered as a CRI (100 mg/m2 over 24 hours) to dogs newly 
diagnosed with MUE, prolonged survival times were noted (Stee 2020). Due to the number of 
dogs still alive at the time of writing, the median survival time was found to be >1095 days. In 
this patient population, survival was not significantly different between those dogs that received 
a single CRI of CA or those that received the CRI in addition to a continued SC protocol (50 
mg/m2 every 12 hours over 48 hours). With that being said, the relapse rate was high in both 
groups, with 60% of the dogs requiring a low dose of prednisone long term (Stee 2020). This 
begs to question whether a different CA protocol of repeated SC injections could provide 
increased efficacy compared to the protocol implemented at that time. While CA continues to be 
a commonly utilized treatment option for MUE survival times well surpassing prednisone or 







2.5 ADVERSE EFFECTS  
While CA is typically well tolerated, adverse effects have been reported in veterinary 
patients receiving this medication. In one of the first studies investigating CA’s ability to cross 
the blood-brain barrier in dogs, it was administered at a dose of 600 mg/m2 intravenously (Scott-
Moncreiff 1991). While this dosage is quite high compared to what is currently recommended 
for dogs being treated for MUE, the only hematologic abnormality reported was mild 
thrombocytopenia in 3 of the 6 dogs when administered as an IV bolus. No hematologic 
abnormalities were noted in dogs who received this dose as a CRI. A more recent study 
investigating the use of CA in dogs with refractory lymphoma found that dogs treated with a 
combination of carboplatin and CA were significantly more likely to develop neutropenia and 
thrombocytopenia than those treated with carboplatin alone (Gillem 2015). While CA certainly 
has the propensity to cause cytopenias, it is also possible that the myelosuppressive effects were 
compounded given that none of the dogs received solely CA. In both of studies, the cytopenias 
reported were mild and not life-threatening (Scott-M 1991, Gillem 2015). 
Other reports have noted other rare adverse effects starting to be reported in dogs. Some 
of these adverse effects were related to the route of administration, including severe calcinosis 
cutis and deep pyoderma present at the interscapular injection site and seizures following 
intrathecal administration (Volk 2012 and Genoni 2016, respectively). They proposed etiology of 
calcinosis cutis in these cases was suspected to be related to the trauma of repeated injections or 
chemical injury to the skin in that region that might favor local mineral deposition, supporting 
rotation of the administration site in future protocols (Volk 2012). Seizures have been seen 
following intrathecal injection of CA; however, this cannot be conclusively linked to CA given 






contrast myelography (Gillem 2015, da Costa 2011). Finally, there has been a single case report 
of drug-induced infiltrative lung disease was diagnosed in a dog being treated for MUE with 
prednisone and CA (Hart 2016). Ultimately, this patient developed respiratory failure indicating 
ventilatory support, and was euthanized 24 hours following initiation of mechanical ventilation 
due to his static condition. The cause of pulmonary toxicosis was not identified in the case, but 
given the temporal association between CA exposure and the development of respiratory distress 
and pulmonary infiltrations (while excluding other causes of the dog’s clinical signs), drug-
induced infiltrative lung disease was highly suspected (Hart 2016).  
Overall, the most common adverse effects are cytopenias with rare reports of 
complications associated with the route of administration. With careful monitoring of laboratory 
work and attention to route of administration, CA can be administered safely to dogs. 
 
2.6 PHARMACOKINETIC STUDIES AVAILABLE IN VETERINARY LITERATURE 
Prior to utilizing CA in our canine population for treatment of intracranial disease, it 
would seem vital to verify that this medication can in fact cross the blood brain barrier to enter 
the central nervous system. Scott-Moncrieff and colleagues executed a study in 1991 that 
evaluated the PK properties of CA in the plasma and cerebrospinal fluid of dogs. In this study, a 
dose of 600 mg/m2 was administered to 10 healthy beagles intravenously in the form of 
intravenous bolus dosing (6 dogs) or as a 12 hours intravenous infusion (4 dogs). It was found 
the CA crosses the blood brain barrier in dogs when given as an intravenous bolus or as a 
constant rate infusion with biphasic elimination (Scott-Moncrieff 1991).  
Further studies on the PK properties of CA and various routes of administration have 






intracranial disease (inflammatory and neoplastic). One study evaluating a single SC injection 
(50 mg/ m2) and a CRI administered over 8 hours (200 mg/m2) found that the CRI administration 
produced steady state plasma concentrations of CA, however, this could not be determined 
following the SC protocol applied as only a single dose was administered (Crook 2013). The 
mean peak concentration achieved (Cmax) was not significantly different with either 
administration route (SC Cmax of 2.88 µg/mL and CRI Cmax of 2.80 µg/mL) (Crook 2013). With 
similar Cmax being achieved with both administration routes, further studies regarding alternative 
SC dosing protocols are warranted to determine if sustained plasma levels can be achieved in 
dogs via repeated SC injections.  
After determining PK parameters of CA in healthy dogs, further studies were indicated in 
clinical patients. A prospective study enrolling 19 client owned dogs with MUE was performed 
to evaluate plasma and serum concentration of CA when administered as a CRI to dogs 
diagnosed with MUE. While the Cmax of plasma reported was lower than that reported in healthy 
dogs (being 1.7 µg/mL as opposed to 2.8 µg/mL in Crook et al.’s 2013 study), all dogs exceeded 
suggested target plasma concentrations 1 µg/mL at time points 1 hour and 8 hours after initiation 
of treatment, indicative of consistent and prolonged exposure in the bloodstream (Early 2016). 
While it is valuable to have verified that CA achieves its proposed target concentration 
when administered as a CRI, understanding the PK properties when administered SC to clinical 
MUE patients is equally as important when considering the benefits associated with receiving a 
SC injection as opposed to a CRI. In turn, a single SC dose of CA (50 mg/m2) was administered 
to 12 dogs with recently diagnosed with MUE, and plasma concentrations were measured over 
the course of 6 hours. In this study, as in other studies pertaining to MUE, all dogs were 






standard. In all dogs, plasma CA measured above 1.0 µg/mL from 30 minutes (first time point) 
up until 120 minutes after administration, having a rapid absorption followed by immediate 
decrease in concentration (Pastina 2017). Knowing that CA reaches its target concentration for 
120 minutes (2 hours) following administration subcutaneously, a dosing protocol involving 
every 2-hour administration to achieve the total dose typically administered as CRI may feasible. 
This conjecture, however, requires appropriate investigation in the PK properties of repeated SC 
injections of CA in clinical MUE patients. 
A more recent investigation was performed evaluating repeated SC dosing protocols of 
CA, which was published after the current study had been designed and patient recruitment 
accomplished. In this 2019 publication, a standard 2-day protocol (50 mg/m2 SC every 12 hour) 
was compared to two novel 1-day protocols (a single 200 mg/m2 SC dose and two 100 mg/m2 SC 
dose every 12 hours) in 4 client owned dogs previously diagnosed with MUE. All four dogs 
received each SC protocol, allowing a 21-day washout period in between (Jones 2019). The 
overall drug exposure for each of the three protocols was similar based on their area under the 
curve calculation. The authors proposed a recommended administration of CA as two doses of 
100-200 mg/m2, 12 hours apart. While this dosing protocol is more convenient than previously 
recommended protocols, it still requires a prolonged day in the hospital for the patient and 
potentially multiple hospital visits depending on the hours of operation of the hospital. 
Additionally, it would be prudent to evaluate these protocols and/or others with a larger sample 
population. Jones et al were the first to investigate the PK properties of SC administration of CA 






CHAPTER 3: PHARMACOKINETICS OF A NOVEL CYTOSINE ARABINOSIDE 
SUBCUTANEOUS PROTOCOL IN DOGS WITH MENINGOENCEPHALOMYELITIS 
OF UNKNOWN ETIOLOGY 
 
3.1 INTRODUCTION 
Meningoencephalomyelitis of unknown etiology (MUE) is a common cause of 
noninfectious inflammatory disease of the central nervous system (CNS) in dogs (Granger 2010, 
Mayousse 2017, Tiploid 1985). The term MUE is an umbrella term used to describe immune-
mediated encephalitides and myelitis, including granulomatous meningoencephalitis (GME), 
necrotizing meningoencephalitis (NME), and necrotizing leukoencephalitis (NLE), SRMA, 
eosinophilic meningoencephalomyelitis (EME), greyhound nonsuppurative meningoencephalitis, 
and spinal-cord only meningomyelitis. Meningoencephalomyelitis of unknown etiology (MUE) 
is an important disease in the field of veterinary medicine given the severity of neurological 
symptoms that can be seen at the time of diagnosis, its guarded prognosis, and the large financial 
investment required by owners for diagnostic testing and treatment. This disease is diagnosed 
based on history, clinical signs, advanced imaging findings, cerebrospinal fluid (CSF) analysis, 
and negative infectious disease testing in the absence of histopathology, which is required for 
definitive diagnosis. Neuroanatomic localization can be multifocal or focal with variable clinical 
signs such as changes in mentation, seizures, paresis, ataxia, vestibular signs, and cranial nerve 
deficits (Baroon 2015, Cornelis 2016, Granger 2010, Nuhsbaum 2002, Tiploid 1995, Vitale 
2019). 
While the underlying etiology of MUE remains unknown, a T-cell immune-mediated 
etiology is highly suspected (Vitale 2019). Immunosuppression has therefore been the target of 
treatment. Various immunomodulatory medications have been used in dogs with MUE, with the 






mean survival times reported for treatment with corticosteroids alone are reported in Table 1. 
Emerging studies have demonstrated improved survival when multimodal treatment is 
implemented. This includes a corticosteroid with one or more of the following adjunctive 
medications: cyclosporine (Jung 2013, Behr 2009, Pakozdy 2009, Gnirs 2006, Adamo 2004), 
mycophenolate mofetil (Woolcock 2016, Baroon 2016), cytosine arabinoside (Lowrie 2016, 
Lowrie 2013, Granger 2010, Behr 2009, Smith 2009, Menaut 2008, Zarfoss 2006, Nuhsbaum 
2002), lomustine (Flegl 2011), vincristine in combination with cyclophosphamide (Smith 2009), 
azathioprine (Wong 2010), procarbazine (Coates 2007), leflunomide (Sato 2017), along with 
radiation therapy (Beckmann 2015, Granger 2010). The mean survival times associated with 
multimodal treatment are on average longer than those reported with corticosteroids alone, 
ranging from 118-1834 days to 14-323 days, respectively. As these ranges imply, mean survival 
times are extremely variable. Additionally, these data are extrapolated from a limited number of 
studies, all of which have fairly small sample sizes. While a wide variety of treatment options 
exists, there is yet to be a standardized protocol recommended for these patients.  
Given that cytosine arabinoside (CA) has been associated with favorable survival times 
and little to no systemic side effects in dogs with MUE (Arnold 2017, Lowrie 2016, Menaut 
2008, Zarfoss 2006, Nuhsbaum 2002), this medication has been used more frequently in practice. 
Many different dosing protocols using CA exist including administration via subcutaneous (SC) 
injection or a constant rate infusion (CRI). A previous study demonstrated a significantly higher 
3-month survival rate in dogs that had received CA via a CRI (100 mg/m2 over 24 hours) for 
their initial treatment when compared to SC administration (Lowrie 2016). For this reason, 
administration of CA via CRI for initial dosing has been widely used amongst veterinary 






additional financial cost to the client, longer duration of hospitalization for the patient, and 
repeated intravenous catheterization, making subsequent treatments more uncomfortable and 
physically challenging to administer. Subsequent treatments with CA are often administered via 
SC injections with no standardized protocol established. While there have been studies 
evaluating the pharmacokinetic properties of CA when administered as a CRI in healthy dogs 
and those with MUE (Crook 2012, Early 2016), the pharmacokinetic properties of SC 
administration of CA has only recently begun to be evaluated (Pastina 2018, Jones 2019). 
Additionally, there is very limited data pertaining to the pharmacokinetic properties of repeated 
SC dosing (Jones 2019). 
The objective of this prospective study was to investigate the PK properties of CA when 
administered as repeated SC injections over 8 hours to dogs with MUE in order to determine if 
this amenable administration protocol is a viable alternative to more laborious CRI 
administration. The primary objective was to describe the PK parameters of CA when 
administered SC over 8 hours and when administered as a CRI over 24 hours. The secondary 
objectives were to determine if CA’s proposed therapeutic target of 1 µg/mL is achieved with 
both routes of administration, and if plasma levels exceed this target throughout the time course 
administered. Finally, short-term outcome of each patient receiving this protocol were reported 
(survivor or death/euthanasia) and classified based upon how many immunomodulatory 
medications they are receiving concurrently with CA. We hypothesize that both routes of 
administration would result in CA concentrations that meet or exceed its proposed therapeutic 
target concentration at 1 hour and 8 hours following initiating of treatment, making this novel SC 
protocol a viable alternative to the CRI protocol. Furthermore, we hypothesize that most dogs 






3.2 MATERIALS AND METHODS  
3.2.1 Animals 
To be considered for enrollment, dogs had to have either magnetic resonance imaging 
(MRI) and/or cerebrospinal fluid (CSF) analysis compatible with inflammatory disease, pertinent 
negative infectious disease testing, and weigh at least 2.5 kilograms. Magnetic resonance 
imaging findings compatible with MUE include multiple, single, or diffuse intra-axial 
hyperintense lesions on T2-weighted (T2W) MR images based on proposed guidelines for 
diagnosis of MUE when histopathology is absent (Granger, 2010). Cerebrospinal fluid analysis 
compatible with MUE included hypercellularity with >50% mononuclear cells based on 
proposed guidelines for diagnosis of MUE when histopathology is absent (Granger, 2010). 
Infectious diseases testing was performed on a case-by-case basis depending upon the patient’s 
history and risk of exposure. This included testing for Blastomycosis dermatitidis, Neospora 
canis, Toxoplasma gondii, Canine Distemper Virus, and Rickettsial disease (Ehrlichia, 
Anaplasma, Bartonella, Borrelia, and Rickettsia).  
All patients underwent a physical and neurological exam performed by a board-certified 
veterinary neurologist or a resident in veterinary neurology supervised by a boarded-certified 
neurologist. Weight, age, breed, gender status, duration of clinical signs prior to diagnosis, and 
current medications were recorded in the medical record, along with the findings from the 
neurological exam and the associated anatomic neurolocalization. All physical examination 
findings were recorded, and patients were excluded from the study if abnormalities present 
contraindicated sampling line placement or frequent handling. All patients enrolled had a CBC 







3.2.2 Experimental design 
A non-randomized crossover study was performed over a one-month period. Dogs 
diagnosed with MUE all initially received a standard CRI protocol of CA intravenously over 24 
hours (200 mg/m2) following diagnosis and were discharged to their owners with instructions to 
receive prednisone or prednisolone (1-2 mg/kg/day orally). Following initial treatment with the 
CRI, dogs returned 4 weeks later for a novel SC protocol of CA administration over 8 hours (50 
mg/m2 every 2 hours). Each dog underwent plasma drug monitoring for the 24 hours following 
initiation of each CA administration protocol (CRI and SC).  
 
3.2.3 Drug administration and sample collection. 
For the CRI administration, a triple-lumen centrally inserted venous catheter (CVC) or 
peripherally inserted venous catheter (PICC) was placed via the previously described modified 
Seldinger technique under sedation for the purpose of both CA administration and sample 
collection, utilizing different ports for drug administration and sample collection (Portillo, 2006). 
Ports utilized for sample collection were flushed with 1 mL of saline to eliminate the possibility 
of any residual CA being present within the port. Then, 3 mL of blood was withdrawn prior to 
sample collection and replaced following sample collection. Finally, the sampling port was 
flushed with 1 mL of heparinized saline and occluded to prevent any retrograde flow between 
sampling time points. Dogs were sedated with up to two of the following medications for CVC 
or PICC placement: dexmedetomidine 3-5 mcg/kg intravenously (IV) (4/8), butorphanol 0.20-
0.40 mg/kg IV (2/8), methadone 0.20-0.25 mg/kg IV (3/8), hydromorphone 0.10 mg/kg IV (2/8), 
and fentanyl 3 mcg/kg IV (1/8). All dogs were then administered CA at 200 mg/m2. Blood 






and 24 hours after initiating treatment the CRI and SC protocols. Immediately following 
collections, samples were placed into lithium heparin tubes and stored in a standard refrigeration 
unit (4ºC). Within 1 hour of collection, samples were centrifuged at 20,000g for 15 minutes, and 
plasma stored at -80ºC until analysis.  
For the SC administration, the same protocol was used to place a CVC or PICC in each 
patient. Dogs were sedated with up to two of the following medications for CVC or PICC 
placement: dexmedetomidine 3-7 mcg/kg IV (8/8), midazolam 0.20 mg/k IV (1/8), butorphanol 
0.30-0.40 mg/kg IV (2/8), methadone 0.20-0.25 mg/kg IV, (4/8), hydromorphone 0.1 mg/kg IV 
(2/8), and alfaxalone 2 mg/kg IV (1/8). All dogs received CA 50 mg/m2 SC every 2 hours for a 
total of 4 doses. Sample collection was the same as for the CRI administration. 
 
3.2.4 Plasma analysis 
Canine plasma samples were analyzed via high-pressure liquid chromatography-tandem 
mass spectrometry (HPLC-MS) in a similar fashion as previous CA pharmacokinetic studies 
(Crook, 2012; Early, 2016; Pastina, 2018). Samples were analyzed with the 5500 QTRAP 
LC/MS/MS system (Sciex, Framingham, MA) in Metabolomics Lab of Roy J. Carver 
Biotechnology Center, University of Illinois at Urbana-Champaign. Software Analyst 1.7.1 was 
used for data acquisition and analysis. The 1200 series HPLC system (Agilent Technologies, 
Santa Clara, CA) includes a degasser, an autosampler, and a binary pump. The LC separation 
was performed on an Agilent SB-Aq column (4.6 x 50mm, 5μm) with mobile phase A (0.1% 
formic acid in water) and mobile phase B (0.1% formic acid in acetontrile). The flow rate was 
0.3 mL/min. The linear gradient was as follows: 0-3 min, 100% A; 10-12 min, 2% A; 12.1-17 






samples were rigorously mixed with 10 µL 1.2 µg/mL 2-Cl-2'-deoxyadenosine and 60 µL 
methanol. The resulting supernatant after centrifugation (1,500 g x 10 min) was subject to the 
instrument analysis injection. The injection volume was 5 µL. Mass spectra were acquired under 
positive electrospray ionization (ESI) with the ion spray voltage was +5500 V.  The source 
temperature was 450°C. The curtain gas, ion source gas 1, and ion source gas 2 were 33, 65, and 
55 psi, respectively. Multiple reaction monitoring (MRM) was used for quantitation: Cytarabine 
m/z 244.1  m/z 112.0; internal standard 2-Cl-2'-deoxyadenosine m/z 286.0  m/z 117.0.  The 
limit of quantitation was 2.5 ng/mL. The method of validation and stability is provided in 
Supplemental Materials. 
  
3.2.5 Outcome assessment 
For each dog, outcome was assigned 3-months following initiation of treatment with CA, 
as outcome at this time-point has been associated with favorable long-term survival in previous 
studies (Lowrie, 2013; Smith, 2009). Outcome was assessed via conversation with the owner in 
person or over the phone, phone conversation with the referring veterinarian, or upon review of 
the medical record. Possible outcomes included: survived-in remission, survived-currently 
receiving 1 oral immunomodulatory medication (prednisone or prednisolone), survived-currently 
receiving 2 or more oral immunomodulatory medications, or died/euthanized.  
 
3.2.6 Statistical analysis 
Descriptive statistics were used to report age, breed, sex, and weight. Continuous data are 
reported as median (range). For both the IV and SC protocols, pharmacokinetic parameters were 






(AUC0-24) using the trapezoidal method, plasma concentrations at 1 h and 8 h after initiating 
treatment (C1 and C8, respectively), and duration of time plasma concentration exceeded 1 
µg/mL (T>1). Time to Cmax (Tmax) was calculated for the SC protocol only. Wilcoxon sign rank 
tests were performed to compare Cmax, C1, C8, and T>1 between the CRI and SC protocols. 
McNemar's tests were used to compare the number of dogs that achieved plasma concentrations 
greater than 1 µg/mL at 1 and 8 h following CA administration between the two administration 
protocols. Because the sampling period for the CRI protocol did not include the terminal phase 
of the time-concentration curve, comparison of AUC between IV and SC protocols were not 
performed. Statistical comparisons were performed using commercial software (Prism 8; 
GraphPad Software) with significance set at P < 0.05. 
 
3.3 RESULTS 
A total of 10 dogs were recruited for enrollment in the study between February 2019 and 
December 2019 based on history, presenting complaint, unremarkable blood work, MRI 
findings, and CSF analysis suggestive of antemortem diagnosis of MUE. Two patients were 
excluded for the following reasons: in one patient, the finalized CSF analysis was not consistent 
with inflammatory disease and another patient was euthanized prior to completion of the study 
protocol due to clinical decline requiring mechanical ventilation. Therefore, a total of 8 dogs met 
the inclusion criteria for this study. 
The median age and weight at presentation was 4.90 (range: 1-10) and 13.20 kilograms 
(range: 2.50-35.10), respectively. The median duration of clinical signs prior to presentation was 
45.80 days (range: 1-257). Demographic and 3-month follow-up information are reported in 






prednisolone) prior to presentation. Upon antemortem diagnosis of MUE, 2/8 were treated with 
clindamycin while awaiting negative infectious disease testing results. All patients received oral 
glucocorticoids (prednisone or prednisolone) at a dosage of 1-2 mg/kg/day. No other 
antimicrobials or antifungals were used. Various medications aside from glucocorticoids were 
utilized on a patient-by-patient basis given the clinical nature of this study, including 
levetiracetam (3/8), phenobarbital (1/8), clindamycin (2/8), methadone (1/8), gabapentin (4/8), 
pantoprazole (3/8), omeprazole (1/8), meclizine (1/8), and maropitant (1/8). 
Time-concentration curves for CRI and SC CA administration are presented in Figure 1, 
and calculated PK parameters are present in Table 4 for both routes of administration. A 
summary of plasma concentrations at various time points in each dog for CRI and SC routes of 
administration in addition to other descriptive statistics may be found in the Supplemental 
Materials (Supplemental Table 1 and Supplemental Table 2, respectively). The Cmax for the SC 
protocol (3.40 µg/mL, range: 1.60-9.70 µg/mL) was significantly higher than for the CRI 
protocol (1.09 µg/mL, range: 0.77-1.67 µg/mL, P = 0.02), as demonstrated in Figure 2. Plasma 
CA concentration at 1 hour and 8 hours following initiation of treatment are demonstrated in 
Figure 3A and 3B, and duration above 1 µg/mL in Figure 3C. Plasma C1 for the SC protocol was 
significantly higher (2.28 µg/mL, range: 0.97-2.67 µg/mL) than for the CRI protocol (0.01 
µg/mL, range: 0-0.45 µg/mL, P = 0.01). Plasma C8 for the SC protocol (1.83 µg/mL, range: 
0.77-2.84 µg/mL) was also significantly higher for the CRI (0.74 µg/mL, range: 0.57-1.11 
µg/mL, P = 0.01). T>1 was significantly higher for the SC protocol (9.25 hours, range: 4.50-
10.50 hours) than for the CRI protocol (3.13 hours, 0-9.75 hours, P = 0.03). Significantly more 
dogs achieved plasma concentrations greater than 1 µg/mL one hour after administration of the 






achieved plasma concentrations greater than 1 µg/mL eight hours after administration of the SC 
protocol (7/8) than the CRI protocol (1/8, P = 0.04). 
 
Five of 8 dogs were alive 3 months following their diagnosis. All five surviving dogs 
(5/8) were receiving the CA SC protocol every 4 weeks. Four surviving dogs (4/5) were 
receiving 1 oral immunomodulatory medication (IMM), and one was receiving more than 2 oral 
IMM (1/5). Two dogs were euthanized after completion of the study period due to lack of 
improvement in their clinical signs (2/8), and one was lost to follow-up (1/8). No adverse effects 
of CA previously reported in dogs receiving CA intravenously or subcutaneously, such as 
thrombocytopenia, neutropenia, calcinosis cutis, or drug-induced infiltrative lung disease, were 
noted in this study population (Gillem, 2015; Hart, 2016; Volk, 2012; Scott-Moncrieff, 1991). 
 
3.4 DISCUSSION 
This study demonstrates that when CA is administered via repeated subcutaneous 
injections over an 8-hour period, it achieves consistent and prolonged exposure in the plasma of 
dogs with MUE, exceeding 1 µg/mL at 1 hour and 8 hours after initiation of treatment. While 
there are many different protocols proposed for CA treatment in dogs with MUE, the 
investigated protocol was established based on the previous research documenting a single SC 
dose of CA (50 mg/m2) achieving sustained plasma levels for 2 hours following administration in 
dogs with MUE (Patina, 2017).  Another study evaluating PK parameters between the different 
routes of administration in healthy dogs found that the SC route did not achieve steady-state 
concentrations, however, the time to reach its maximum plasma concentration was 1 hour with 
an elimination half-life of 1.15 hours (Crook, 2013). Similarly, plasma CA levels following CRI 






minutes (Early 2016). Knowing that CA should theoretically reach its target concentration within 
1 hour of administration and that plasma levels should be sustained for 2 hours following SC 
administration, a new dosing protocol involving every 2-hour administration to achieve the total 
dose typically administered as a CRI was conceptualized. In order to administer the 
recommended CRI dose of 200 mg/m2 in 2-hour increments on an outpatient bases, a dog would 
indicate four 50 mg/m2 SC injections, to total an 8-hour duration of treatment. Keeping these 
data in mind, a protocol of 50 mg/m2 SC every 2 hours was proposed and investigated. 
Previous pharmacokinetic studies have found that when administered as a CRI, CA 
achieves sustained plasma levels throughout administration, indicative of prolonged exposure in 
the blood of both healthy dogs and dogs with MUE (Crook, 2013; Early, 2016). In both of these 
reports, a minimum target concentration of 1 µg/mL CA was applied and has continued to be 
utilized as a threshold concentration for more recent investigations (Patina, 2018). Based on the 
duration of treatment prescribed by this protocol, we investigated plasma CA levels at 1 hour and 
8 hours following initiation of treatment to ensure that the therapeutic target was met throughout 
the duration of treatment, as has been done in previous studies (Early 2016). In the present study, 
this minimum target concentration was achieved when using the SC protocol, with median Cmax, 
C1, and C8 being 3.4 µg/mL (range: 1.60-9.70 µg/mL), 2.28 µg/mL (range: 0.97-2.67 µg/mL), 
and 1.83 µg/mL (range: 0.77-2.84 µg/mL), respectively. The median Cmax following CRI 
administration was significantly lower, measuring 1.09 µg/mL (range: 0.77-1.67 µg/mL). In fact, 
plasma CA levels in dogs receiving the CRI protocol often failed to reach the therapeutic target 
at 1 hour and 8 hours following initiation of treatment, measuring 0.01 µg/mL (range: 0-0.45 
µg/mL) and 0.74 µg/mL (range: 0.57-1.11 µg/mL), respectively. When receiving the CRI 






dog (1/8) did so at C8, whereas nearly all dogs (7/8) achieved CA concentrations greater than 1 
µg/mL at C1 and C8 for the SC protocol. The CRI protocol did, however, provide a longer 
duration of detectable CA in the plasma. It is unknown whether CA is time or concentration 
dependent in dogs, so the significance of this finding is unknown. If, for example, a longer 
duration of CA administration is associated with a prognostic benefit, this may make the 
investigated SC protocol less advantageous. Studies continue to use a minimum therapeutic 
target concentration that has been extrapolated from the human literature in which passive 
diffusion of CA becomes significant only at concentrations great than 1 µg/mL in sarcoma cells 
in vitro, and true therapeutic drug levels are unknown in dogs (Mulder, 1975). Based on 
previously used therapeutic targets, however, the SC protocol appears to reach superior 
concentrations for a longer duration of time when compared to the CRI protocol. 
To the author’s knowledge, this is the first proposed CA protocol utilizing repeated SC 
injections that can be fully administered on an outpatient basis. A recently published SC protocol 
recommends a higher dose of CA (100-200 mg/m2) requiring 12 hours between treatments 
(Jones, 2019). This study also found that plasma CA concentrations are known to rise in a near-
linear fashion with increasing doses of CA, although the significance of this is unknown as CA 
may be concentration or time dependent in dogs and requires further investigation. A dose of 50 
mg/m2 of CA over multiple treatment days (50 mg/m2 every 12 hours for 2 days) has been 
implemented anecdotally and in a previous study, which can present logistical and financial 
challenges from an owner perspective in addition to increased stress incurred to the patient 
(Lowrie, 2013). It is unknown if this type of prolonged drug exposure is associated with any 
degree of a prognostic benefit. It has been demonstrated that dogs with MUE receiving CA via a 






compared to those receiving CA via a SC protocol (50 mg/m2 every 12 hours) over 2 days 
(Lowrie, 2013). These historical findings support initial treatment with a CRI (as was performed 
in the present study at a dose of 200 mg/m2), however, subsequent treatments with an alternative 
protocol could be considered provided that minimum therapeutic targets continue to be achieved. 
We have demonstrated that repeated SC injections of 50 mg/m2 administered every 2 hours over 
an 8-hour period maintains minimum therapeutic target of CA throughout its course of treatment. 
Repeated SC injections also have the benefit of being less invasive than a CRI, in that they do 
not require intravenous catheterization. Additionally, administration of treatment over an 8-hour 
period reduces stress to the patient and to the owner by decreasing the duration and number of 
hospital visits required in a short period of time. Finally, five dogs (5/8) remained alive 3 months 
following diagnosis and only one patient (1/8) required more than 1 oral immunomodulatory 
medication during the follow-up period, indicating that this protocol may be associated with a 
positive outcome. A larger study population, however, would be required to establish statistical 
significance. Considering previously published data and the data provided by the present study, 
the authors recommend the following CA administration protocol for dogs with MUE: CA 100-
200 mg/m2 administered via CRI at the time of diagnosis, followed by 50 mg/m2 SC every 2 
hours for 4 doses (to total 200 mg/m2) every 4 weeks. 
 
3.5 LIMITATIONS  
3.5.1 Lack of histopathologic diagnosis of MUE  
This study is not without limitations. As is the case for many studies pertaining to MUE, 
his study is lacking histopathologic diagnoses. The authors applied previously established 






likelihood of a true positive diagnosis. In addition, so as to mirror a clinical setting, infectious 
disease testing was performed as deemed necessary by individual clinicians based on the 
patient’s history and the possibility of exposure to infectious agents. Infectious disease testing 
was therefore not standardized, but determined on a case-by-case basis. While surgical biopsy 
can be considered in these cases as well, doing so would increase morbidity and possibly 
mortality of our patient population and likely would not provide a survival benefit. For this 
reason, surgical biopsy was not recommended in any dogs in our study population. Necropsy was 
performed on the one dog that was euthanized during the study period, however, confirming a 
diagnosis of nonsuppurative (granulomatous) meningitis involving the brain and spinal cord.  
 
3.5.2 Inclusion of myelitis and optic neuritis under the umbrella of MUE 
Another potential limitation of this study is the inclusion of dogs with myelitis and optic 
neuritis. All patients in our study met the following proposed guidelines as suggested by Granger 
et al: older than 6 months of age with evidence of multifocal or diffuse CNS disease, 
hypercellular CSF analysis with >50% mononuclear (monocytes/lymphocytes) cells, and 
negative pertinent infectious testing. Notably, Granger et al. does not recommend inclusion of 
patients with spinal cord MUE given the current lack of objective diagnostic criteria to 
distinguish these cases from other myelopathies. In our cases diagnosed with spinal cord MUE 
(3/9), antemortem diagnosis of MUE was extrapolated from Granger et al.’s aforementioned 
proposed guidelines for noninfectious inflammatory meningoencephalitis given that this is how 
this disease continues to be diagnosed in practice. Inclusion of patients with optic neuritis is also 
not recommended when brain MRI and CSF analysis is normal (Granger 2010). However, the 






in the optic nerves bilaterally on their MRI in addition to a mononuclear pleocytosis upon CSF 
analysis, suggestive of diffuse meningeal involvement. Certainly, there remains a strong 
indication to continue investigating for an underlying etiology noninfectious inflammatory 
immune-mediated diseases of the meninges, brain, spinal cord, and optic nerves.  
 
3.5.3 Treatment order not randomized 
The treatment order was not randomized due to the prognostic benefit documented in 
dogs with MUE receiving the CRI protocol as their initial treatment (Lowrie, 2016). Based on 
this and our institution’s current practices, it was therefore decided that all patients would receive 
CA as a CRI first. 
 
3.5.4 Other treatment modalities not standardized  
Treatment modalities outside of CA and glucocorticoid dosages were not standardized in 
the present study. Other treatment modalities would be nearly impossible to standardize as dogs 
with MUE are treated on an individual basis dependent upon response to care, possibly having to 
consider other systemic comorbidities, and often times having been started on some form of 
treatment prior to presentation at a referral institution. It is therefore possible that antimicrobial 
therapy, variable glucocorticoid dosages, anticonvulsants, analgesia, gastrointestinal support, and 
individualized sedation protocols for central venous catheter placement could have altered the 
hemodynamics and ultimately metabolism of CA in individual patients. This theoretically could 
have altered the PK properties described, although previous studies have not documented any 
significant difference in the PK properties of CA in clinically affected dogs receiving CA alone 






(Early, 2016).  
 
3.5.5 Lack of collection of time points in the terminal phases of the time-concentration curve for 
the CRI protocol 
One final limitation was a lack of collection of time points in the terminal phases of the time-
concentration curve for the CRI protocol, impeding our ability to compare AUC between both protocols. 
This would have provided additional information pertaining to drug exposure and clearance but would not 
have altered the conclusions drawn in relation to maintenance of a minimum therapeutic target 
concentration with the designated times (1 and 8 hours). 
 
 
3.6 PROJECT CONCLUSIONS  
In conclusion, the investigated CA SC protocol achieved its proposed therapeutic target 
concentration in dogs with MUE. Interestingly, the therapeutic target was not reached when 
implementing the CRI protocol, warranting further investigation of minimum therapeutic targets 
in dogs with MUE as they may be different following SC and CRI administration. Despite the 
limitations present in this study, it demonstrates that repeated SC injections when given in 2-hour 
increments can maintain plasma concentration of CA exceeding its minimum therapeutic target 
throughout the duration of treatment. Additionally, the investigated protocol may also be given 
on an outpatient basis, thus reducing hospitalization time, the iatrogenic trauma associated with 
repeated catheterization, and client cost when compared to other administration protocols. 
Further study of a larger population of dogs with MUE is needed to assess effects on outcome, 
ideally with more standardized medication protocols, and to determine if a different target 







3.7 FUTURE DIRECTIONS 
3.7.1 Effect of proposed protocol on outcome 
Further study of a larger population of clinically affected dogs is needed to assess effects 
on outcome. While 5 of the 8 dogs treated in this study were alive 3 months following initiation 
of the investigated CA protocol, this is a fairly small sample size.  
 
3.7.2 Effect of higher target concentrations on outcome 
It has now been documented that plasma CA concentrations rise in a nearly linear fashion 
as dosage increases; however, drug exposure nor incidence of adverse effects seem affected 
(Jones, 2019). Additionally, even receiving dosages 3 times what is typically used in practice, 
dogs have had no clinically significant adverse effects reported (Scott-Moncrieff, 1991). Further 
study investigating the effect on outcome when implementing various dosages of CA when 
administered as a CRI (for example 100 mg/m2 compared to 200 mg/m2 at the time of 
diagnosis) and when subsequently administered as intermittent SC injections (for example 50 
and 100 mg/m2 every 2 hours for 4 total doses) would be indicated to provide more precise 







TABLES AND FIGURES 
 
Table 1: Mean survival time (MST) in dogs with MUE receiving glucocorticoids (GCC) alone. 
Treatment Diagnosis MST (Days) Sample Size (n) References 
Prednisone or prednisolone 
1 mg/kg PO q12h 
MUE 602 16 Mercier & Barnes 
Heller 2015 
Prednisolone 
0.6-1.4 mg/kg/day PO (GME) 





11 Flegel et al 2011 
Prednisolone 
5-30 mg/kg/day PO (6/7 dogs) 
Dexamethasone 
1 mg/kg/day PO (1/7 dogs) 
Suspect 
GME* 
28 7 Pakozdy 2009 
Prednisolone 
1 mg/kg PO q12h 
NME 58 7 Jung 2007 
Meningoencephalitis of unknown etiology (MUE). Granulomatous meningoencephalitis (GME). Necrotizing 
meningoencephalitis (NE). Necrotizing meningoencephalitis (NME). 









Table 2: Mean survival time (MST) in dogs with MUE treated receiving multimodal therapy. 
Treatment Diagnosis MST (Days) Sample Size (n) References 
GCC + azathioprine MUE 1834 40 Wong et al 2010 




Pakozdy et al 2008 
Gnirs 2006 
Jung 2007 
Adamo & O’Brien 2004 
GCC + cytosine 
arabinoside 






Lowrie et al 2013 
Smith et al 2009 
de Stefani et al 2007ǁ 
Menaut et al 2008 
Zarfoss et al 2006 
GCC + leflunomide MUE Unavailable 5 Gregory et al 1998ǂ 
GCC + lomustine GME, NME 457, 329 14 Flegel et al 2011 
GCC + mycophenolate MUE 250-731 25 
25 
Baroon et al 2016 
Woolcock et al 2015 
GCC + procarbazine Suspect GME 420 21 Coats et al 2007 
GCC + vincristine + 
cyclophosphamide 
 MUE Unavailable 
 
8 Smith et al 2009* 






Beckmann et al 2015 
Muñana & Luttgen 
1998 
Glucocorticoids (GCC). Meningoencephalitis of unknown etiology (MUE). Granulomatous meningoencephalitis (GME). 
Necrotizing meningoencephalitis (NE). Necrotizing meningoencephalitis (NME). 
ǀ 59/80 dogs alive 3 months following diagnosis; 100% (59/59) survived to 12 months. 
ǁ 6/9 alive at follow-up (range: 4-30 months). 
ǂ All alive at follow-up (range: 4-11 months). 









Table 3: Signalment, presenting complaint, duration of clinical signs, neuroanatomical 








Table 4: Calculated pharmacokinetic parameters for cytosine arabinoside when administered via 











Figure 1: Plot of mean plasma cytosine arabinoside concentration (CA) time course in dogs with 
MUE (n=8) for 24 hours following initiation of a standard CRI protocol and a novel SC protocol. 








Figure 2: Plot of peak cytosine arabinoside (CA) concentrations in dogs with MUE (n = 8) 
during administration of a standard CRI protocol and a novel SC protocol. Horizontal bars 











Figure 3: Plot of plasma CA concentration at 1 hour (a) and 8 hour (b) following initiation of 
treatment, and time that plasma concentration was measured to be > 1 µg/mL (c) in dogs with 
MUE (n = 8) during administration of a standard CRI protocol and a novel SC protocol. 
Horizontal bars represent the mean. 
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APPENDIX A: ASSAY VALIDATION 
The quantitative LC/MS/MS method was validated with 3 control samples (15 ng/mL, 300 
ng/mL, and 3000 ng/mL) for consistency of results and extraction efficiency of the assay. 
Stability of cytosine arabinoside in plasma during storage was assessed by use of control plasma 
with spiked standards (cytosine arabinoside at 15 ng/mL, 300 ng/mL, and 3000 ng/mL). The 
spiked samples were stored at 10°C for 72 hours. These samples were processed on the day of 
testing and run together with samples extracted from control plasma spiked with freshly prepared 
standards. Between-run accuracy (expressed as % nominal value ± standard deviation) was 
within 9% of the expected concentrations, measuring 92.4 ± 6.1, 91.0 ±3.0, and 93.8 ±2.0 for 15 
ng/mL, 300 ng/mL, and 3000 ng/mL control samples, respectively. Within-run precision 
(expressed as relative standard deviation over the expected concentrations) was 6.7, 0.3, and 0.1 
for 15 ng/mL, 300 ng/mL, and 3000 ng/mL control samples, respectively. Between-run precision 
(expressed as relative standard deviation over the expected concentrations) was 1.8, 0.1, and 0.1 








APPENDIX B: RAW DATA TABLES 
 
Raw Data Table 1. CRI plasma [CA] in dogs with MUE, including mean, standard deviation (SD), 
standard error (SE), and 95% confidence interval (CI) for each sampling time point. 
 
t(h) Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Dog 6 Dog 7 Dog 8 Mean SD SE 95%CI 
0 0.00 0.00 0.00 0.14 0.09 0.00 0.00 0.00 0.03 0.05 0.02 0.05 
1 0.45 0.02 0.00 0.35 0.01 0.35 0.00 0.00 0.15 0.20 0.07 0.16 
2 0.31 0.46 0.00 0.49 0.11 0.61 0.00 0.13 0.26 0.24 0.08 0.20 
3 1.67 0.38 0.00 0.68 0.25 0.68 0.00 0.70 0.54 0.54 0.19 0.45 
4 1.59 0.87 0.00 0.40 0.48 0.69 0.02 1.16 0.65 0.55 0.19 0.46 
5 0.84 0.60 0.00 0.56 0.53 0.80 0.03 1.19 0.57 0.40 0.14 0.34 
6 0.68 0.72 0.48 0.73 0.64 0.88 0.53 1.23 0.74 0.24 0.08 0.20 
7 0.82 0.93 0.51 0.61 0.93 0.92 0.62 0.99 0.79 0.18 0.06 0.15 
8 0.72 0.61 0.79 0.60 0.57 0.85 0.77 1.11 0.75 0.18 0.06 0.15 
10 0.70 0.89 0.89 0.60 0.77 0.84 0.54 0.93 0.77 0.14 0.05 0.12 
12 0.56 1.07 0.73 0.78 0.89 0.83 0.61 1.43 0.86 0.28 0.10 0.23 
14 0.40 0.97 0.95 0.78 0.74 0.81 0.72 0.74 0.76 0.18 0.06 0.15 
16 0.49 0.82 1.04 0.78 0.72 1.28 1.34 0.72 0.90 0.29 0.10 0.25 
20 † † 1.10 0.55 0.77 0.66 0.96 0.76 0.80 0.20 0.08 0.25 
24 † † 1.06 0.72 0.91 0.07 0.92 1.16 0.81 0.39 0.16 0.30 








Raw Data Table 2. SC plasma [CA] in dogs with MUE, including mean, standard deviation (SD), 
standard error (SE), and 95% confidence interval (CI) for each sampling time point. 
 
t(h) Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Dog 6 Dog 7 Dog 8 Mean SD SE 95%CI 
0 0.00 0.00 0.19 0.14 0.06 0.00 0.00 0.00 0.05 0.08 0.03 0.06 
1 0.97 2.16 2.41 2.67 1.42 2.16 2.39 2.5 2.09 0.59 0.21 0.49 
2 0.70 1.52 1.82 1.43 2.12 1.73 1.89 1.37 1.57 0.43 0.15 0.36 
3 1.21 2.97 3.61 2.88 1.90 3.24 2.73 2.6 2.64 0.76 0.27 0.64 
4 0.91 2.53 3.18 1.52 ‡ 2.57 2.52 1.77 2.14 0.77 0.29 0.72 
5 1.60 9.70 4.91 2.77 0.78 3.95 3.68 2.17 3.70 2.77 0.98 2.31 
6 1.03 2.16 2.75 1.87 1.66 3.19 3.31 1.5 2.18 0.83 0.29 0.69 
7 1.57 1.77 4.35 3.35 2.54 3.99 3.45 2.52 2.94 1.01 0.36 0.84 
8 0.77 1.11 2.74 1.95 1.70 2.84 2.64 1.33 1.88 0.79 0.28 0.66 
10 0.06 1.58 0.82 0.59 0.73 1.44 0.79 0.00 0.75 0.57 0.20 0.47 
12 0.00 0.39 0.20 0.15 0.26 0.54 0.08 0.00 0.20 0.19 0.07 0.16 
14 0.00 0.05 0.58 0.01 0.22 0.17 0.00 0.00 0.13 0.20 0.07 0.17 
16 0.00 0.00 0.03 0.06 0.06 0.06 0.00 0.00 0.03 0.03 0.01 0.02 
20 † † 0.14 0.05 0.02 0.00 0.00 0.00 0.03 0.05 0.02 0.06 
24 † † 0.03 0.02 0.03 0.00 0.00 0.00 0.01 0.01 0.01 0.02 
† Data unavailable due to lack of samples at these timepoints 
‡ Data unavailable due to technical error during sample processing 
